• DOI:10.1016/j.jaci.2016.08.010
Corpus ID: 3626708

Omalizumab facilitates rapid oral desensitization for peanut allergy

@article{MacGinnitie2017OmalizumabFR,
  title={Omalizumab facilitates rapid oral desensitization for peanut allergy},
  author={Andrew MacGinnitie and R. Rachid and Hana Gragg and S. Little and Paul R Lakin and A. Cianferoni and J. Heimall and M. Makhija and R. Robison and S. Chinthrajah and John J Lee and Jennifer S LeBovidge and T. Dominguez and C. Rooney and M. O. Lewis and J. Koss and Elizabeth Burke-Roberts and K. Chin and T. Logvinenko and J. Pongracic and D. Umetsu and J. Spergel and K. Nadeau and L. Schneider},
  journal={The Journal of Allergy and Clinical Immunology},
  year={2017},
  volume={139},
  pages={873–881.e8}
}

Andrew MacGinnitie, R. Rachid, +21 authors L. Schneider

Published 2017

Medicine

The Journal of Allergy and Clinical Immunology

Background: Peanut oral immunotherapy is a promising approach to peanut allergy, but reactions are frequent, and some patients cannot be desensitized. The anti‐IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more rapid peanut updosing and decrease reactions. Objective: We sought to evaluate whether omalizumab facilitated rapid peanut desensitization in highly allergic patients. Methods: Thirty‐seven subjects were randomized to omalizumab (n = 29) or placebo… CONTINUE READING

View on Wolters Kluwer

jacionline.org

Save to Library

Create Alert

Cite

Launch Research Feed